Biologics are the cutting edge of medicine, bringing dramatic improvements in quality of life and health for patients. But they can be fragile and degrade quickly. Transporting biotech treatments at scale to hospitals requires extra care to prevent losses and ensure that personalized medicines make it to the right patients.
Due to their unique construction, biologics and other complex medications must be transported at much colder temperatures than standard vaccines and medicines. In-depth monitoring is needed to prevent temperature variations that can damage costly products.
The products shipped through the biopharma logistics chain represent a high-value investment for manufacturers and patients. Losing limited cell lines and biologics that take significant time to produce can be financially devastating. Losses of personalized medicine also delay much-needed patient treatment and can result in worsening patient outcomes.
Specialized handling requirements are needed to protect temperature-sensitive and time-sensitive medicines during shipment. This helps ensure that fragile biologics, cells, and gene therapies arrive at a destination in good condition.
The standard cold chain was developed primarily for traditional medicines and vaccines. Modern biologics, human tissues and blood, monoclonal antibodies, and some mRNA vaccines require deep-cold storage that goes beyond what standard refrigeration provides. A combination of unique protein structures and temperature-sensitive ingredients means these medicines can break down quickly if not kept extremely cold. Avoiding temperature excursions of any length becomes essential, which means closer monitoring and multiple layers of validated packaging and thermal protection are used in biopharma logistics.
The biotech logistics network requires additional rigor around temperature control and security. The basic path to delivery remains the same: arranging storage and transportation, executing the shipment, and providing visibility throughout.
The traditional cold chain isn't cold enough to protect biotech products in transport. Distributors need vehicles and transport containers capable of keeping fragile cell and gene therapies at extremely cold temperatures.
While insulin, many vaccines, and medications can be transported at refrigerated temperatures of 2°C to 8°C, some mRNA vaccines and biologics require frozen storage (around -15°C to -25°C) or ultra-cold storage (around -60°C to -90°C), depending on the product's stability requirements. Distributors transporting cell and gene therapies must keep them at cryogenic temperatures below -150°C to prevent degradation.
Preparing a shipment for delivery and maintaining a closely documented chain of custody add additional complexity to biopharma logistics. Because temperature control is critical, manufacturers and distributors use validated packaging to transport biotech products. Validated packaging has undergone rigorous testing to confirm it can maintain specified temperature ranges and protect medications from physical damage during transit.
Additional training is necessary to ensure pharma products are shipped safely, which means manufacturers may hire specialty pharma couriers to transport biotech freight. Established chain-of-custody processes, trained drivers, and access to ultra-cold and cryogenic storage make these specialty couriers a strong choice for pharmaceutical companies.
Many cryogenic shipments contain personalized therapies, making chain of custody another key component of biopharma logistics. Some of these treatments, such as autologous cell therapies, are made from a specific patient's own cells and have no therapeutic value for anyone else. In addition, delivering the wrong cell therapy to the wrong person can cause serious patient harm.
Delivering the right personalized medication to the right patient requires maintaining a digital audit trail showing handoffs, arrival times, and locations. Alongside this, biopharma logistics providers maintain a chain of identity, a process that continuously verifies that a specific treatment is matched to its intended patient.
Manufacturers of biologics and personalized medicine often start as researchers developing new treatments in small facilities. Once a treatment shows clinical success, they must transition into large-scale production. Biotech startups in the expansion phase must also build a transportation network capable of delivering their therapies to hospitals across the country and around the world.
Selecting a 3PL that provides biopharma logistics solutions for startups eases the growing pains of scaling up. The right partner provides scaling transport and a reliable ultra-cold chain network. Biotech startups can work with one provider from the early days of small-scale biotech and pharma logistics through full commercial launch and long-term growth.
An experienced biopharma logistics provider can also help develop the transportation network the startup will use to reach hospitals and patients. The provider can adjust the distribution process as the biotech grows into an established company, taking on shipments with tighter deadlines and handling increasing volume.
With an established 3PL partner, biotechs gain access to existing cold storage warehousing, freight relationships, and transportation and dock management systems that help maintain both the ultra-cold chain and chain of custody.
Biopharma logistics covers a wide and specialized area of medication transport and delivery. The following FAQs are a good starting point for your research.
Pharma logistics maintains the cold chain and chain of custody for vaccines and medications stored at standard refrigerated temperatures. Biotech logistics takes cold storage and chain of custody a step further, as many biologics and cell or gene therapies require ultra-cold or cryogenic temperatures, and some are personalized to a specific patient.
Cell and gene therapies require cryogenic storage in specialized containers designed to maintain temperatures of -150°C and below throughout transit. These biotech treatments are continuously monitored for temperature and location as part of the chain-of-custody process. Shippers, manufacturers, and hospital providers also follow a chain-of-identity process to ensure that personalized medications reach the right patient.
An experienced biopharma logistics provider is well suited to partner with startups entering the launch phase. These 3PLs should have an established process for handling ultra-cold and cryogenic shipments, use real-time monitoring software, and consistently maintain the chain of custody.
Scaling up a biotech transportation network requires clear visibility into shipments as they arrive at the dock. Knowing arrival times, dwell times, and chain-of-custody details helps reduce the risk of expensive and patient-harming losses. Opendock helps managers and operators safeguard these valuable shipments at the dock with real-time dock activity displays, digital scheduling, configurable rules for cold-receiving doors, and audit-ready reporting.